Pretomanid Medication Guide: Core Agent in the BPaL Regimen for Drug-Resistant Tuberculosis

　　Drug Overview

　　Pretomanid is a novel nitroimidazole-class anti-tuberculosis agent that exerts bactericidal activity by inhibiting mycobacterial cell wall synthesis and energy metabolism.It demonstrates unique efficacy against Mycobacterium tuberculosis in the dormant,hypometabolic state,filling an important gap left by conventional anti-tuberculosis drugs.The original brand formulation is available in a 200 mg×26-tablet pack,with the reference originator version priced at approximately 600+USD internationally,with lower-cost generic alternatives available in certain markets.

　　Efficacy Highlights:The BPaL Regimen Breakthrough

　　Pretomanid is a cornerstone of the BPaL regimen(bedaquiline+pretomanid+linezolid),indicated for the treatment of extensively drug-resistant tuberculosis(XDR-TB)and multidrug-resistant tuberculosis(MDR-TB)in patients with rifampicin resistance or isoniazid intolerance.The pivotal Nix-TB clinical trial demonstrated that the BPaL regimen achieved an 87.1%favorable outcome rate after 6 to 9 months of treatment,significantly higher than the approximately 30–40%rate observed with conventional treatment regimens.The addition of pretomanid has dramatically shortened the treatment course for drug-resistant TB from the traditional 18–24 months to just 6–9 months,and the entirely oral formulation eliminates the need for injectable agents,substantially improving patient adherence and quality of life.

　　Potent Bactericidal Activity and Low Resistance Profile

　　Pretomanid exhibits potent bactericidal activity against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis,with no cross-resistance to existing anti-tuberculosis agents.Its unique anaerobic bactericidal mechanism effectively targets dormant bacterial populations,addressing a critical limitation of conventional therapies.Multiple clinical studies have shown that the resistance rate to pretomanid is extremely low,at less than 1%,making the risk of acquired resistance during long-term treatment highly manageable.

　　Indicated Patient Populations

　　Pretomanid is indicated for the following groups of patients with drug-resistant tuberculosis:first,patients with extensively drug-resistant tuberculosis(XDR-TB),defined as resistance to both fluoroquinolones and second-line injectable agents;second,patients with multidrug-resistant tuberculosis(MDR-TB)who are also resistant to fluoroquinolones or intolerant to isoniazid;third,patients with MDR-TB who have failed or are intolerant to standard treatment regimens;and fourth,patients with drug-resistant TB who are not candidates for injectable therapy,such as those with concurrent renal impairment or hearing loss.Importantly,pretomanid is not indicated for drug-susceptible tuberculosis(for which first-line agents remain effective)or for latent tuberculosis infection.

　　Contraindications and Precautions

　　Hypersensitivity to pretomanid or any of its excipients is an absolute contraindication.Relative contraindications include severe hepatic impairment(Child-Pugh Class C),severe renal impairment(eGFR<30 mL/min/1.73 m²),pregnancy(due to insufficient safety data)and breastfeeding.Since pretomanid is typically administered in combination with bedaquiline and linezolid,regular monitoring of liver function,renal function and complete blood count is required during treatment(linezolid may cause myelosuppression),along with periodic ECG monitoring(bedaquiline may cause QTc interval prolongation).

　　Summary

　　The introduction of pretomanid represents a major breakthrough in the treatment of drug-resistant tuberculosis.The BPaL regimen,with pretomanid at its core,offers the significant advantages of high efficacy,short treatment duration and fully oral administration,dramatically improving outcomes for patients with extensively drug-resistant and multidrug-resistant tuberculosis.This agent is indicated primarily for patients with XDR-TB and specific subsets of MDR-TB,and should be used under the guidance of a tuberculosis specialist with close monitoring of safety parameters throughout the treatment course.